64Cu-LLP2A for Imaging Hematologic Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Multiple MyelomaLow-Grade LymphomaFollicular LymphomaMarginal Zone LymphomaLymphoplasmacytic LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

64Cu-LLP2A

64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)

DEVICE

PET/CT

The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER